Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose cyclophosphamide without stem cell rescue in scleroderma.

C V Tehlirian1, L K Hummers, B White

  • 1Department of Medicine, Johns Hopkins Medical Institution, Baltimore, Maryland, USA.

Annals of the Rheumatic Diseases
|November 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adolescent cannabinoid type 1 receptor (CB1R) blockade mitigates the effects of adolescent social instability stress (SS) on socially directed behaviour in female rats.

Psychoneuroendocrinology·2026
Same author

Empathic and agentic artificial intelligence in nursing: perspectives on a human-centered framework for cancer care navigation in the United States.

ESMO real world data and digital oncology·2026
Same author

Autophagy is essential for survival and function of polyploid giant cancer cells under therapeutic stress.

Cancer letters·2026
Same author

Demonstration of a mobile optical clock ensemble at sea.

Nature communications·2025
Same author

Relative sensitivity of plastic scintillator: A comparative analysis with 60Co gamma rays, deuterium-deuterium, and deuterium-tritium neutrons.

The Review of scientific instruments·2024
Same author

Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.

BMC health services research·2022
Same journal

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Annals of the rheumatic diseases·2026
Same journal

Commentary on 'Assessing the performance of AI chatbots in answering patients common questions about low back pain'.

Annals of the rheumatic diseases·2026
Same journal

Response to Correspondence on 'Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial'.

Annals of the rheumatic diseases·2026
Same journal

Correspondence on 'Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial' by Hawkins et al.

Annals of the rheumatic diseases·2026
Same journal

Response to correspondence on 'Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis' by Kaundal et al.

Annals of the rheumatic diseases·2026
Same journal

Correspondence on 'Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis' by Kaundal et al.

Annals of the rheumatic diseases·2026
See all related articles

High-dose cyclophosphamide without stem cell rescue showed significant skin score improvement in scleroderma patients. While generally safe, one patient died from infection, highlighting the need for careful monitoring.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Scleroderma is a chronic autoimmune disease characterized by skin thickening and potential organ damage.
  • Current treatments for diffuse cutaneous scleroderma have limitations, necessitating exploration of novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the safety and efficacy of high-dose cyclophosphamide (CYC) without stem cell rescue in patients with active diffuse cutaneous scleroderma.
  • To assess the impact of this treatment on skin scores, functional status, and overall disease severity.

Main Methods:

  • An open-label, single-site study treated six patients with active diffuse cutaneous scleroderma using high-dose intravenous cyclophosphamide (200 mg/kg total) followed by granulocyte colony-stimulating factor.
  • Efficacy was measured by the modified Rodnan skin score (mRSS), Health Assessment Questionnaire-Disability Index (HAQ-DI), physician global assessment (PGA), and pulmonary function tests.

Related Experiment Videos

Main Results:

  • Five of six patients showed significant improvement in mRSS within one month, with sustained benefits in three patients for up to 24 months.
  • Physician global assessment and HAQ-DI scores improved by 72% and 79% respectively at three months in five patients.
  • One patient died early due to infection after neutrophil recovery, representing the only serious adverse event.

Conclusions:

  • High-dose cyclophosphamide without stem cell rescue can induce clinically significant improvements in skin manifestations and disease severity in diffuse cutaneous scleroderma.
  • The treatment demonstrates potential as a therapeutic option, though careful monitoring for adverse events, including infection, is crucial.